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Abstract
Introduction: Twin pregnancy with complete hydatidiform mole represents a very rare obstetric problem.
Management of such cases is always problematic because the possibility of fetal survival should always be
weighed against the risk of complications of molar pregnancy.
Case presentation: A 34-year-old Caucasian woman presented to our center with mild vaginal bleeding. Our
patient was 16 weeks pregnant after a seven-year period of primary infertility. She became pregnant following a
non-prescribed regimen of clomiphene citrate extending from the second day to the 13th day of her last cycle. A
transabdominal ultrasound examination revealed a twin pregnancy with complete hydatidiform mole and a
coexisting fetus. Serum b human chorionic gonadotropin was falsely low as identified by serial dilution of the
sample (the ‘hook effect’). Our patient refused termination of pregnancy and she was hospitalized for strict
observation and follow-up. Unfortunately, she developed an attack of severe vaginal bleeding and a hysterotomy
was performed. The fetus died shortly after birth.
Conclusions: Twin pregnancy with complete hydatidiform mole represents a matter of controversy. We suggest
that conservation should always be considered whenever tertiary care services and strict observation are available.
Introduction
Twin pregnancy with complete hydatidiform mole and
coexisting fetus is rarely seen during clinic practice. The
incidence ranges from 1 in 20,000 to 1 in 100,000 preg-
nancies [1]. Diagnosis in such cases can be simply made
by obstetric ultrasound examination but the decision
whether to conserve or not is always problematic. Tradi-
tionally, termination of pregnancy was indicated to avoid
the unacceptable risk of complications of complete
molar pregnancy such as early onset pre-eclampsia,
thyrotoxicosis and increased risk of persistent tropho-
blastic disease [2]. However, complete hydatidiform
mole is possibly associated with advanced maternal age
and the use of assisted reproductive techniques, and this
reflects how difficult the decision of termination is for
such couples [3]. Our case report represents one such
patient who conceived after a relatively long period of
infertility and repeated medical trials for conception. In
this article, we report a case of second trimester twin
pregnancy with a huge complete hydatidiform mole that
was managed conservatively according to our patient’s
request and circumstances. We also discuss the falsely
low b human chorionic gonadotropin (hCG) results that
were revealed during follow-up in what is known as the
‘hook effect’. The hook effect is another interesting phe-
nomenon that should be considered in patients with
complete molar pregnancy and low serum b-hCG.
Case presentation
A 34-year-old Caucasian woman, gravida 1 para 0, pre-
sented to our hospital with repeated attacks of mild
vaginal bleeding. Our patient, according to her sure
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She had a history of primary infertility for seven years
preceding this pregnancy, and she had sought medical
advice for delayed conception one year after marriage.
Male factor infertility was excluded by a single semen
analysis and she was informed that her hysterosalpingo-
graphy was quite normal; she was given medical treat-
ment that she could not recall to improve her cycles
(these were infrequent and irregular over the last five
years). She used these medications for about four
months after which she reported some improvement in
her cycles but conception did not occur. A hormonal
profile was ordered and our patient was examined trans-
vaginally by ultrasound. Subsequently, she was informed
she had bilateral polycystic ovarian syndrome. Her phy-
sician prescribed clomiphene citrate (Clomid, Global
Napi, Egypt) 100 mg for five days beginning on the sec-
ond day of her cycle. Our patient continued taking the
drug without ovulation monitoring and the regimen was
repeated with an increasing dose up to 200 mg daily for
six successive months. Laparoscopic ovarian drilling was
performed and our patient resumed using clomiphene
citrate three months after the operation without pre-
scription. Two months prior to admission, she took 250
mg of clomiphene citrate (five tablets per day) beginning
from the second day onwards until the 13th day of the
cycle.
Our patient had a missed period immediately after this
haphazard regimen. Pregnancy was confirmed by a urine
pregnancy test then by a trans-vaginal ultrasonographic
examination that was carried out six weeks and three
days after her last menstrual period. According to this
ultrasound report, the gestational sac corresponded to
seven weeks of gestation. However, there was no com-
ment regarding the presence of theca lutein ovarian
cysts. She did not follow-up with her pregnancy until
she reached the 16th week of gestation. At that time,
she experienced recurrent attacks of vaginal bleeding
that she described as mild and dark colored. Apart from
pallor and tachycardia, our patient appeared quite nor-
mal on general examination; her pulse was 106 beats/
minute, blood pressure was 125/85 and her temperature
was 37.2°C. Abdominally, her uterine fundal level was
equivalent to 28 weeks and the uterus was dewy in con-
sistency in most of its mass. A transabdominal ultra-
sound examination revealed a huge complete
hydatidiform mole occupying the lower pole of the
uterus and a coexisting fetus with its placenta that were
enclosed within a separate sac (Figure 1). Our patient
was admitted to our hospital and full laboratory investi-
gations were ordered. Her blood test results revealed
microcytic hypochromic anemia and her hemoglobin
level was 9.6 g/dL. Other investigations were normal. In
spite of her testing positive, her serum b-hCG level was
relatively low for a patient with complete molar preg-
nancy (8354 mIU/mL and 7799 mIU/mL in two serum
samples drawn two days apart). The technician did not
suspect any technical error and he confirmed the
 
 
 
 
Figure 1 Ultrasound picture of complete hydatidiform mole with coexisting fetus and placenta.
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sibility of falsely low results and accordingly, a senior
specialist was consulted. She repeated the test with serial
dilutions and b-hCG was found to be 1.876 million
mIU/mL. Our patient was counseled about the risk of
continuation of this pregnancy and the low possibility of
fetal survival. However, our patient refused intervention
and insisted on conservation.
The choice of conservative management was quite dif-
ficult; our patient was kept under strict observation and
she was followed up using a four-hour interval chart for
vital signs. Blood picture, renal chemistry (urea and
creatinine), liver enzymes and thyroid function tests
were ordered twice weekly, vaginal bleeding was
observed and our patient was asked to report any pain,
bleeding or other issues during the period of conserva-
tion. Our patient was offered genetic amniocentesis but
she absolutely refused the procedure. On day 3, an
increase in blood pressure above 140/90 mmHg was
reported and it was found to be increasing (Figure 2).
However, dipstick testing for albumin in her urine gave
a negative result. Anti-hypertensive drugs were not
given in order not to mask her actual blood pressure.
She experienced palpitation, flushing and excessive
sweating from day five and the thyroid function test was
repeated; the results indicated thyrotoxicosis (T4 = 3.26
ng/dL, free T3 = 5.95 pg/mL, thyroid stimulating hor-
mone (TSH) = 0.022 μIU/mL). Two attacks of mild
vaginal bleeding were reported on days five and nine.
The dipstick testing for albumin in urine became posi-
tive (1 plus) on day seven and the results became worse
over the next few days reaching 4 plus on day 10. Our
patient was recounseled about these unacceptable com-
plications (thyrotoxicosis and severe pre-eclampsia) and
for the low possibility of fetal survival. Again, the patient
refused termination. Two days later, the patient devel-
oped a severe attack of vaginal bleeding; a hysterotomy
was inevitable. She delivered a 680 g viable boy with no
apparent congenital anomalies; the placenta was com-
plete, about 15 cm in diameter and adjacent but identifi-
able from the coexisting molar pregnancy. The baby
died half an hour later in the neonatal intensive care
unit. A histopathological study confirmed the diagnosis
of benign complete hydatidiform mole. Unfortunately,
karyotyping was not available.
Her serum b-hCG level was followed up after termina-
tion; it dropped progressively until it became negative
after 70 days and remained so for 12 successive months
(Figure 3). Serial dilution of the sample was no longer
needed after termination.
Figure 2 Blood pressure follow-up mean readings during conservative management.
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Few cases of complete hydatidiform mole with a coexist-
ing fetus have been reported over the last two decades.
This broad term can be classified into three major types:
(1) twin gestation in which one twin is a diploid fetus
with a normal placenta (46 chromosomes, 23 maternal
and 23 paternal) and the other twin is a complete hyda-
tidiform mole (46 chromosomes of paternal origin) with
no fetus (this is applied to our case report). (2) Single-
ton gestation consisting of a triploid fetus with partial
hydatidiform mole placenta (69 chromosomes, 23
maternal and 46 paternal). (3) Twin gestation in which
one twin is a diploid fetus with normal placenta (46
chromosomes, 23 maternal and 23 paternal) and the
other twin is a triploid fetus with partial hydatidiform
mole placenta (69 chromosomes, 23 maternal and 46
paternal) [4]. Categorization of the case is essential for
proper management. Unlike partial hydatidiform mole
that is commonly associated with multiple fetal anoma-
lies and is managed by immediate termination of preg-
nancy [5], reported cases of twin pregnancy with
complete hydatidiform mole (including our case) are not
associated with fetal anomalies in the coexisting fetus; in
some cases the mother has even given birth to fetuses
that survived [6].
However, twin pregnancy with complete hydatidiform
mole has a higher risk of maternal complications than
partial hydatidiform moles; the same risk also applies to
twin pregnancy with complete hydatidiform mole. These
complications include early onset pre-eclampsia, thyro-
toxicosis and persistent trophoblastic disease (PTD).
Because of case rarity, the incidence of these complica-
tions cannot be exactly assessed in comparison with
complete molar pregnancy; however, the incidence of
PTD in reported case series varies from 19% to 50%
[2,7]. The reason for this high incidence has not yet
been clarified.
Accordingly, the management of these cases remains
problematic: the fair possibility of fetal survival is
weighed against the expected risk of maternal complica-
tions, and for this reason, many reported cases were
managed by immediate termination. However, some
authors support the option of conservation under strict
hospital-based observation and follow-up. In this case,
we support the latter policy for the following reasons.
First, conservative management of some reported cases
was successful, with fetal survival [5]. Second, most
expected complications can be diagnosed by strict fol-
low-up and clinical observation. Third, although the risk
of PTD cannot be excluded during conservative man-
agement, this risk does not seem to increase with
advanced gestational age [2]. According to these find-
ings, we suggest that conservative management should
always be a choice in such patients.
Amniocentesis is expected to be beneficial in decision
making; a triploid fetus would be expected to be
Figure 3 Serum b-human chorionic gonadotropin (hCG) follow-up before and after termination of pregnancy after elimination of the
‘high-dose hook effect’.
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would be recommended. A diploid fetus (46XX or 46XY
of maternal and paternal origins) indicates a viable fetus
with a normal placenta and therefore, pregnancy can be
allowed to continue [4]. With regard to our patient, the
option of amniocentesis was refused and we were obli-
gated to manage our patient conservatively according to
her will. Unfortunately, our patient experienced serious
complications during conservation and hysterotomy was
indicated; the fetus was alive but did not survive. How-
ever, as our patient was managed conservatively as long
as possible and she did not experience any adverse post-
operative outcomes including gestational trophoblastic
disease, these findings may support the relative safety of
conservation of these cases.
The falsely low result for serum b-hCG represents
another interesting point in our patient’s case; this is
described as the ‘high-dose hook effect’.T h i se f f e c ti s
not specific for b-hCG. It occurs when there is an inor-
dinate amount of substance being measured by an
immunoassay; this causes the formation of incomplete
antibody-antigen complexes. Accordingly, below a cer-
tain threshold concentration, the assay will reflect the
concentration of the substance correctly. Above this
concentration, the assay will record falsely lower results
as the concentration rises higher. This can be corrected
by dilution of a sample and this was exactly what we
did in this case [8].
It is infeasible to correlate between the occurrence of
complete hydatidiform mole with a coexisting fetus and
ovulation induction, particularly with clomiphene citrate,
because the number of reported cases is limited. How-
ever, the association between complete hydatidiform
mole and ovulation induction has not been confirmed;
the incidence of complete hydatidiform mole following
ovulation induction with clomiphene citrate was 1:659
[9,10]. However, Piura et al. reported 30 cases of twin
pregnancy with complete hydatidiform mole and a co-
existent fetus. Of these, nine cases (30%) were preceded
by ovulation induction with either hMG/hCG (eight
cases) or clomiphene citrate (one case). Five out of eight
patients who received human menopausal gonadotropin
(hMG)/human chorionic gonadotropin (hCG) were
exposed to assisted reproductive technologies (in vitro
fertilization/embryo transfer (IVF/ET) in three women,
intra-cytoplasmic sperm injection/embryo transfer
(ICSI-ET) in two women) [4]. This correlation may need
further study and explanation.
Conclusions
Twin pregnancy with complete hydatidiform mole is a
rare condition that can be diagnosed by obstetric ultra-
sound examination. We cannot confirm or deny a corre-
lation between this case and ovulation induction because
the number of reported cases is still limited. Manage-
ment of these patients is controversial. However, we
suggest that conservative management is always a choice
whenever strict hospital-based observation is available.
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